Jaguar to Participate in UAE Tech Tour and MGF Spring Event in Napa Valley
February 1, 2017 – Jaguar Animal Health, Inc. (NASDAQ: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, is pleased to announce that its president and CEO, Lisa Conte, will participate in exclusive, invitation-only Monaco Growth Forums Ltd. (“MGF”) roadshow and conference events in February and March 2017.
The Company will first present in a series of group and one-on-one meetings during the MGF Winter Tech Tour in Dubai and Abu Dhabi from February 20-23, 2017. Ms. Conte will also participate in several group and one-on-one presentations and meetings during the highly regarded MGF Spring Edition investor conference in Napa Valley, California from March 29-31, 2017, which will feature leading healthcare companies. The Tech Tour is MGF’s premier emerging company roadshow while the MGF Spring Conference serves as one of the group’s signature events of the year.
Jaguar Animal Health is engaged in the development of a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health. The Company’s pipeline currently includes prescription drug product candidates for nine indications across multiple species, including the treatment of acute diarrhea in dogs and cats, and non-prescription products targeting seven species including adult horses, dairy calves, piglets, and other farm/production animals.
“I look forward to presenting at both of these events to familiarize investors with Jaguar and our mission to deliver first-in-class gastrointestinal products to animals in need around the world,” commented Conte.
Andreea Porcelli, CEO of Monaco Growth Forums Ltd., noted the significance of the upcoming investor events. “We are thrilled to introduce emerging health care companies to select audiences in the U.A.E. and Napa Valley, California on an ongoing basis; Jaguar Animal Health is a great example of such a company.”
For more information or to RSVP for the Tech Tour and MGF Spring Conference events and one-on-one investor meetings with Jaguar Animal Health, contact Sevinc Bermek, Events Coordinator: email@example.com or visit http://swissgrowthforum.io/.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high-value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding Jaguar’s intention to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise